 Cytochrome P-450 CYP3A
"Cytochrome P-450 CYP3A" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cytochrome P-450 suptype that has specificity for a broad variety of lipophilic compounds, including STEROIDS; FATTY ACIDS; and XENOBIOTICS. This enzyme has clinical significance due to its ability to metabolize a diverse array of clinically important drugs such as CYCLOSPORINE; VERAPAMIL; and MIDAZOLAM. This enzyme also catalyzes the N-demethylation of ERYTHROMYCIN.
| Descriptor ID |
D051544
|
| MeSH Number(s) |
D08.244.453.400 D08.811.682.662.582.353 D08.811.682.690.708.170.250 D12.776.422.220.453.400
|
| Concept/Terms |
Cytochrome P-450 CYP3A- Cytochrome P-450 CYP3A
- Cytochrome P 450 CYP3A
- P-450 CYP3A, Cytochrome
- Erythromycin N-Demethylase
- Erythromycin N Demethylase
- N-Demethylase, Erythromycin
- Cytochrome P450 3A
- P450 3A, Cytochrome
- CYP3A
- Cytochrome P-450IIIA
- Cytochrome P 450IIIA
- P-450IIIA, Cytochrome
Cytochrome P-450 CYP3A5- Cytochrome P-450 CYP3A5
- Cytochrome P 450 CYP3A5
- P-450 CYP3A5, Cytochrome
- Cytochrome P450 3A5
- 3A5, Cytochrome P450
- P450 3A5, Cytochrome
- CYP3A5
Cytochrome P-450 CYP3A4- Cytochrome P-450 CYP3A4
- Cytochrome P 450 CYP3A4
- P-450 CYP3A4, Cytochrome
- Cytochrome P450 3A4
- Taurochenodeoxycholate 6-alpha-Monooxygenase
- 6-alpha-Monooxygenase, Taurochenodeoxycholate
- Taurochenodeoxycholate 6 alpha Monooxygenase
- CYP3A4
|
Below are MeSH descriptors whose meaning is more general than "Cytochrome P-450 CYP3A".
Below are MeSH descriptors whose meaning is more specific than "Cytochrome P-450 CYP3A".
This graph shows the total number of publications written about "Cytochrome P-450 CYP3A" by people in this website by year, and whether "Cytochrome P-450 CYP3A" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 | | 1999 | 0 | 1 | 1 | | 2000 | 0 | 1 | 1 | | 2001 | 0 | 3 | 3 | | 2003 | 0 | 3 | 3 | | 2005 | 1 | 2 | 3 | | 2006 | 0 | 3 | 3 | | 2007 | 1 | 0 | 1 | | 2011 | 1 | 0 | 1 | | 2013 | 2 | 0 | 2 | | 2014 | 1 | 0 | 1 | | 2015 | 4 | 0 | 4 | | 2016 | 1 | 1 | 2 | | 2018 | 0 | 1 | 1 | | 2019 | 0 | 1 | 1 | | 2020 | 1 | 1 | 2 | | 2021 | 1 | 0 | 1 | | 2022 | 1 | 0 | 1 | | 2023 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Cytochrome P-450 CYP3A" by people in Profiles.
-
Pratt VM, Cavallari LH, Fulmer ML, Gaedigk A, Hachad H, Ji Y, Kalman LV, Ly RC, Moyer AM, Scott SA, van Schaik RHN, Whirl-Carrillo M, Weck KE. CYP3A4 and CYP3A5 Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase. J Mol Diagn. 2023 09; 25(9):619-629.
-
Alghamdi A, Seay S, Hooper DK, Varnell CD, Darland L, Mizuno T, Lazear D, Ramsey LB. Tacrolimus pharmacokinetics are influenced by CYP3A5, age, and concomitant fluconazole in pediatric kidney transplant patients. Clin Transl Sci. 2023 10; 16(10):1768-1778.
-
Gaedigk A, Boone EC, Turner AJ, van Schaik RHN, Chernova D, Wang WY, Broeckel U, Granfield CA, Hodge JC, Ly RC, Lynnes TC, Mitchell MW, Moyer AM, Oliva J, Kalman LV. Characterization of Reference Materials for CYP3A4 and CYP3A5: A (GeT-RM) Collaborative Project. J Mol Diagn. 2023 09; 25(9):655-664.
-
Rodriguez-Antona C, Savieo JL, Lauschke VM, Sangkuhl K, Dr?gem?ller BI, Wang D, van Schaik RHN, Gilep AA, Peter AP, Boone EC, Ramey BE, Klein TE, Whirl-Carrillo M, Pratt VM, Gaedigk A. PharmVar GeneFocus: CYP3A5. Clin Pharmacol Ther. 2022 12; 112(6):1159-1171.
-
Mutawi TM, Zedan MM, Yahya RS, Zakria MM, El-Sawi MR, Gaedigk A. Genetic variability of CYP2D6, CYP3A4 and CYP3A5 among the Egyptian population. Pharmacogenomics. 2021 04; 22(6):323-334.
-
Vyhlidal CA, Chapron BD, Ahmed A, Singh V, Casini R, Shakhnovich V. Effect of Crohn's Disease on Villous Length and CYP3A4 Expression in the Pediatric Small Intestine. Clin Transl Sci. 2021 03; 14(2):729-736.
-
Roberts TA, Wagner JA, Sandritter T, Black BT, Gaedigk A, Stancil SL. Retrospective Review of Pharmacogenetic Testing at an Academic Children's Hospital. Clin Transl Sci. 2021 01; 14(1):412-421.
-
Chapron BD, Dinh JC, Toren PC, Gaedigk A, Leeder JS. The Respective Roles of CYP3A4 and CYP2D6 in the Metabolism of Pimozide to Established and Novel Metabolites. Drug Metab Dispos. 2020 11; 48(11):1113-1120.
-
Ogungbenro K, Wagner JB, Abdel-Rahman S, Leeder JS, Galetin A. A population pharmacokinetic model for simvastatin and its metabolites in children and adolescents. Eur J Clin Pharmacol. 2019 Sep; 75(9):1227-1235.
-
Meier R, Bi C, Gaedigk R, Heruth DP, Ye SQ, Leeder JS, Fridley BL. Ontogeny-related pharmacogene changes in the pediatric liver transcriptome. Pharmacogenet Genomics. 2018 03; 28(3):86-94.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|